A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib ...

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

A retrospective study explored the impact of preexisting cardiovascular disease on adverse events in patients with hematologic malignancies receiving BTK inhibitors. Prevalence of CVAEs is high among ...

Updated results from a Phase 2 study of WM patients who switched to BRUKINSA after becoming intolerant to other BTK inhibitors, including ibrutinib and acalabrutinib, show that most adverse events ...

Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Nurix Therapeutics offers promising targeted protein degradation treatments for cancer and autoimmune diseases. Find out what ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally ...

Studies of BRUKINSA ® (zanubrutinib), BTK CDAC degrader BGB-16673 and BCL2 inhibitor sonrotoclax featured in invited talks and oral presentations SAN MATEO, Calif., October 16, 2024--(BUSINESS ...

BeiGene has seven presentations at IWWM 2024, and Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at ...